PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 02:05:00 17/05/2024 pm IST | ||
| 19.34 EUR | +1.10% |
|
| Current month | +0.47% | ||
| 1 month | -14.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 19.34 | +1.10% |
| 16/24/16 | 19.13 | +2.30% |
| 15/24/15 | 18.7 | -9.97% |
| 14/24/14 | 20.77 | -1.75% |
| 13/24/13 | 21.14 | +3.12% |
Delayed Quote Deutsche Boerse AG
Last update May 17, 2024 at 02:05 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KJJ |
| ISIN | DE000VD0KJJ0 |
| Date issued | 19/02/2024 |
| Strike | 981.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 18.52 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.29 € |
|---|---|
| Lowest since issue | 17.12 € |
| Spread | 0.29 € |
| Spread % | 1.48% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.1
USD
Average target price
850.4
USD
Spread / Average Target
+10.28%
- Stock Market
- Certificates
- Certificat
